



## Biotechnology and Industrial Microbiology

# Streptomyces globosus DK15 and Streptomyces ederenensis ST13 as new producers of factumycin and tetrangomycin antibiotics



Ivana Charousová\*, Juraj Medo, Lukáš Hleba, Soňa Javoreková

Slovak University of Agriculture in Nitra, Faculty of Biotechnology and Food Sciences, Department of Microbiology, Tr. A. Hlinku 2, 949 76, Nitra, Slovak Republic

## ARTICLE INFO

## Article history:

Received 12 June 2017

Accepted 13 December 2017

Available online 1 March 2018

Presented by Dr. Solange I. Mussatto

## Keywords:

Streptomyces

16S rRNA

MALDI-TOF MS

Tetrangomycin

Factumycin

## ABSTRACT

Fifty seven soil-borne actinomycete strains were assessed for the antibiotic production. Two of the most active isolates, designed as *Streptomyces* ST-13 and DK-15 exhibited a broad range of antimicrobial activity and therefore they were selected for HPLC fractionation against the most suppressed bacteria *Staphylococcus aureus* (ST-13) and *Chromobacterium violaceum* (DK-15). LC/MS analysis of extracts showed the presence of polyketides factumycin (DK15) and tetrangomycin (ST13). The taxonomic position of the antibiotic-producing actinomycetes was determined using a polyphasic approach. Phenotypic characterization and 16S rRNA gene sequence analysis of the isolates matched those described for members of the genus *Streptomyces*. DK-15 strain exhibited the highest 16S rRNA gene sequence similarity to *Streptomyces globosus* DSM-40815 (T) and *Streptomyces toxytricini* DSM-40178 (T) and ST-13 strain to *Streptomyces ederenensis* DSM-40741 (T) and *Streptomyces phaeochromogenes* DSM-40073 (T). For the proper identification, MALDI-TOF/MS profile of whole-cell proteins led to the identification of *S. globosus* DK-15 (accession number: KX527570) and *S. ederenensis* ST13 (accession number: KX527568). To our knowledge, there is no report about the production of these antibiotics by *S. globosus* and *S. ederenensis*, thus isolates DK15 and ST13 identified as *S. globosus* DK-15 and *S. ederenensis* ST-13 can be considered as new sources of these unique antibacterial metabolites.

© 2018 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Since people started suffering from diseases caused by infectious microorganisms, the quest for their remedies led to the discovery of a large number of antibiotics from

microorganisms.<sup>1</sup> Most of the research was dedicated to study the polyketide bioactive compounds.<sup>2</sup> One of the most important and well acknowledged group of the prolific producers of polyketide antibiotics are the actinomycetes, mainly terrestrial representatives of the genus *Streptomyces*.<sup>3</sup> Polyketides have played an important role in the antibiotic drug discovery with most antibacterial drugs being derived from a natural product or natural product lead.<sup>4</sup> Examples of natural products with the polyketide structure include the

\* Corresponding author. Tel.: +421 91702930812.

E-mail: [ivanacharousova@gmail.com](mailto:ivanacharousova@gmail.com) (I. Charousová).

<https://doi.org/10.1016/j.bjm.2017.12.007>

1517-8382/© 2018 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

tetrangomycin and factumycin. Tetrangomycins belong to the group of polyketide angucyclinones, naturally occurring benzaanthraquinones that had been isolated from *Streptomyces rimosus* and *Streptomyces griseus*.<sup>5–8</sup> Angucyclinones, benz[a]anthraquinone derivatives isolated from *Streptomyces* spp. have attracted much attention due to their broad and strong biological activities, mainly antiviral, antifungal, and antitumor.<sup>5,9–10</sup> Immunosuppressive function of tetrangomycin by reducing the transcription of cytokine genes and the inhibitory activity of tetrangomycin against methicillin resistant *Staphylococcus aureus* (MRSA) was described by Özakin et al.<sup>11</sup> Factumycin is a linear polyketide elfamycin compound and had been isolated from *Streptomyces lavendulae* and *Streptomyces griseus*.<sup>12–14</sup> According to Thaker et al.<sup>15</sup> a screen of factumycin in combination with known antibiotics revealed unexpected synergy with tetracyclines, offering a possible new application of factumycin as a lead in Gram-negative targeted antibiotic combination therapy. Identification of factumycin antibiotic has high importance, because Gram - negative pathogens are becoming increasingly antibiotic resistant and consequently a serious clinical challenge.<sup>15</sup>

Therefore, an attempt has been made to isolate the antibiotic-producing actinomycetes with emphasis on the selection and the detailed identification of *Streptomyces* polyketide-producers.

## Material and methods

### Soil samples and isolation of actinomycetes

Actinomycetes were isolated by the dilution agar plating method from the forest soils located in Vietnam, Phu Quoc National Park (10°09'33.49"S 103°59'07.02"E) and in Sardinia, Foresta di Monte Pisanu (40°25'30.24"S 8°58'34.72"E). An aliquot of 0.1 ml of solution was taken and spread over the surface of starch-casein medium.<sup>16</sup> Plates were incubated at 30 °C and monitored after 7 days. The selected strains were maintained by cultivation on the ISP2 medium<sup>17</sup>, incubated at 30 °C for 10 days and stored at – 20 °C in the presence of glycerol (30% v/v). For all acquired actinomycete isolates, 16S rRNA sequences as well as microscopic (shape of spore chains) and macroscopic morphology (colors of aerial and substrate mycelium, soluble pigments and melanin) were studied in accordance with the guidelines established by the International Streptomyces Project.<sup>17</sup>

### Screening for antimicrobial activity

The morphologically different actinomycete isolates were screened against four Gram - positive bacteria [*Bacillus subtilis* (DSM 10), *Micrococcus luteus* (DSM1790), *Staphylococcus aureus* (Newman), *Mycobacterium smegmatis* (ATCC 700084)], four Gram - negative bacteria [*Escherichia coli* (DSM 1116), *Escherichia coli* (TolC), *Pseudomonas aeruginosa* (PA14), *Chromobacterium violaceum* (DSM 30191)], two yeasts [*Candida albicans* (DSM 1665), *Pichia anomala* (DSM 6766)] and one filamentous microscopic fungus *Mucor hiemalis* (DSM 2656) obtained from DSMZ (German Collection of Microorganisms and Cell Cultures), Braunschweig, Germany and ATCC (American Type Culture

Collection), Manassas, VA 20110, USA. Raw extracts were prepared from 20 ml of 5 day old liquid culture using ethyl acetate (Sigma-Aldrich, USA) according to Wink (2014). Ethylacetate was evaporated and extract was dissolved in 1 ml of ethylacetate: acetone: methanol (1:1:1) solution. Detection of biological activity was carried out by preparing 4 - 6 h cultures of indicator bacteria followed by dilution with Mueller-Hinton (MH) broth (Merck, Germany) and yeast and fungi by dilution with Mycosel broth<sup>18</sup> to obtain 0.01 McFarland turbidity. The antimicrobial activity of streptomycetes was performed by using the broth micro - dilution method<sup>19</sup> in 96 - well microplates (BRAND, Germany). The dose in well A corresponds to the extract made from 1.33 ml *Streptomyces* liquid culture per 1 ml of the inoculated broth. Concentration decreased 2 fold in wells B-H. The readings were made after 24 h of incubation through visual observation of the growth.

### HPLC and LC/MS analysis of selected crude extracts

The most active raw extracts were selected for the fractionation by liquid - chromatography (Agilent 1100) equipment. The wavelength monitoring was performed at 210 and 360 nm. Sample (5 µl) was injected onto a HPLC column (X-Bridge 3.5 µm, 2.1x100 mm; Waters, Milford, USA). Separation was performed using the buffers A2: 950 ml H<sub>2</sub>O, 50 ml acetonitrile + 0.05 mM (385 mg.l<sup>-1</sup>) ammonium acetate + 40 µl acetic acid; B2: 50 ml H<sub>2</sub>O, 950 ml acetonitrile, 0.05 mM (385 mg.l<sup>-1</sup>) ammonium acetate + 40 µl acetic acid and a DAD detector (200–400 nm). Fractions (0.15 ml) from the HPLC column were collected in a 96 well plates every 0.5 min and dried with heated nitrogen in MiniVap (Porvair Sciences, UK) for 45–60 min at 40 °C. Afterwards, each well was filled with 150 µl of the selected formerly inhibited test microorganisms and incubated at 30 °C for 24 h. Due to the fact that inhibited wells were visible, the extracts were applied to an LC–MS system [(Agilent 1200 series with DAD detector (200–600 nm) in connection with a maXis UHR–TOF mass spectrometer (Bruker Daltonics, USA)] for peak–activity correlation. Samples were analyzed using a Waters ACQUITY UPLC BEH C18 Column, 2.1 x 50 mm, 1.7 µm. The mobile phase consisted of H<sub>2</sub>O with 0.1% formic acid as solvent A and CH<sub>3</sub>CN with 0.1% formic acid as solvent B at a flow rate of 0.6 ml.min<sup>-1</sup>. The gradient was as follows: 0.5 min 5% B, 19.5 min 95% B and 10 min 95% B. Equilibration time between samples was 5 min. The column temperature was maintained at 40 °C. The main software for processing of results was Data Analysis included in the Compass-software from Bruker (USA).

### Genomic DNA isolation, PCR conditions and phylogenetic analysis of the most active isolates

For the taxonomic identification, the 16S rRNA gene of the selected streptomycetes was sequenced. The isolation of genomic DNA was done by the method described by Sambrook et al.<sup>20</sup> and amplified by PCR using primers F27 and R1492 according to Cook and Meyers.<sup>21</sup> The reaction mixture was made in a total volume of 50 µl (5 µl of 10 × DreamTaq Green PCR buffer, 5 µl of 2 mmol.dm<sup>-3</sup> dNTP, 2 µl of each 10 µmol.dm<sup>-3</sup> primer, 0.3 µl Taq DNA polymerase and 0.5 µl of template DNA (approximately 20 ng)). The PCR reaction ran

in the thermo cycler Biometra T Personal (Germany) under the following conditions: 95 °C for 3 min, 40 cycles of 95 °C for 30 sec, 56 °C for 30 sec, 72 °C for 90 sec and final extension at 72 °C for 10 min. The PCR products were purified with Exonuclease I and Thermosensitive Alkaline Phosphatase (Sigma-Aldrich, USA).

For a rough classification, the 16S rRNA genes were sequenced in MacroGen Company, South Korea. The obtained 16S rRNA sequences were checked for quality and assembled using the program SeqMan II. The similarity and homology of the 16S rRNA gene sequences were analyzed with the similar existing sequences available in the data bank of NCBI using BLAST search (<http://www.ncbi.nlm.nih.gov/BLAST>). The phylogenetic tree was constructed with the Maximum - Likelihood method<sup>22</sup> using PhyML<sup>23</sup>, with bootstrap values based on 1000 replications.

### Cultural and biochemical characteristics

For the taxonomic identification, additional to the 16S rRNA gene sequences and morphological traits, physiological and biochemical features of the isolates DK15 and ST13 were determined. Physiological criteria such as a sodium chloride resistance was tested on ISP9 medium supplemented with 2.5, 5, 7.5 and 10% of NaCl, utilization of different carbon sources (glucose, mannitol, arabinose, inositol, mannose, fructose, galactose, rhamnose, sucrose, xylose) was tested on ISP9 medium with the final concentration of carbon sources adjusted to 1%, pH (levels of 2-9) and temperature (4, 25, 28, 30, 37 and 42 °C) tolerance was tested on the ISP2 medium. Commercially available test kits such as an ApiZym<sup>®</sup> and ApiCoryne<sup>®</sup> (bioMérieux, France) were used for the biochemical characterisation. The Api stripes were inoculated following by manufacturer's manual. The observed characteristics were compared with the phylogenetically related type cultures obtained from German Collection of Microorganisms and Cell Cultures (DSMZ), Braunschweig, Germany.

### MALDI-TOF MS identification

For the MALDI-TOF MS analysis, cellular proteins were extracted according to Loucif *et al.*<sup>24</sup>. For both strains, four extractions were performed, and 1 µl of each suspension was deposited on the MALDI-TOF steel target plate (Bruker Daltonics, Germany) in three replicates. The plate was allowed to dry at room temperature and then overlaid with 1 µl of matrix solution containing α-cyano-hydroxycinnamic acid (SigmaAldrich, USA) saturated with acetonitrile (50%), trifluoroacetic acid (2.5%), and ultrapure water. This mixture was allowed to co-crystallize with the samples. Analysis of protein spectra was performed with the Microflex LT MALDI-TOF MS spectrometer. The measurements were taken in the linear positive ion mode with voltage of 20 kV over a mass range of 2–20 kDa. The resulting spectra were analyzed using MALDI Biotyper, and flexAnalysis (Bruker Daltonics). The obtained spectra were compared with our own created database from type *Streptomyces* cultures obtained from DSMZ, Braunschweig, Germany, which included all the most phylogenetically related species. For the clustering of the *Streptomyces* species, a mean

**Table 1 – Dilution stages of the crude extracts prepared from isolates DK-15 and ST-13.**

Indicator microorganisms	Dilution stages (A-H)	
	ST-13	DK-15
<i>Bacillus subtilis</i> (DSM10)	G	F
<i>Chromobacterium violaceum</i> (DSM30191)	C	G
<i>Escherichia coli</i> (DSM1116)	B	B
<i>Escherichia coli</i> (TolC)	C	C
<i>Micrococcus luteus</i> (DSM1790)	G	D
<i>Pseudomonas aeruginosa</i> (PA14)	-	A
<i>Mycobacterium smegmatis</i> (ATCC700084)	F	F
<i>Staphylococcus aureus</i> (Newman)	H	E
<i>Mucor hiemalis</i> (DSM2656)	A	C
<i>Pichia anomala</i> (DSM6766)	A	D
<i>Candida albicans</i> (DSM1665)	A	B

Dilution stages represented stepwise 2-fold dilution of crude extracts (A – crude extract from 1,33 ml of *Streptomyces* culture in 1 ml of inoculated media, B – 0.66 ml.ml<sup>-1</sup>; C – 0.66 ml.ml<sup>-1</sup>; D – 0.33 ml.ml<sup>-1</sup>; E – 0.17 ml.ml<sup>-1</sup>; F – 0.08 ml.ml<sup>-1</sup>; G – 0.04 ml.ml<sup>-1</sup>; and H – 0.02 ml.ml<sup>-1</sup>)

spectra projection (MSP) dendrogram was constructed with MALDI Biotyper 3.1.


## Results

Antimicrobial activity of the crude extracts and identification of the antibacterial compounds by LC/MS analysis

To establish effective bacteria for the control of human pathogens, a total of 57 actinomycetes were isolated from the forest soil samples. 28 isolates representing 10 species were acquired from Vietnam soil while 29 isolates of 8 species were found in Sardinia soil. Out of all 57 isolates, 8 did not show any antimicrobial activity, 13 low activity (A-B dilution of crude extract), 34 high (C-F), and 2 very high (G-H) based on the results from a classical approach of assessing microplates for the growth inhibition. Two of the most active strains were designed as ST13 and DK15. As shown in Table 1, the crude extracts exhibited high antimicrobial activities against Gram - positive bacteria and against Gram-negative bacterium *Chromobacterium violaceum* DSM30191, but weak activity against *Escherichia coli* DSM1116 and *Pseudomonas aeruginosa* PA14.

Although the nature and type of the active antibacterial compounds were not clear, the prominent antibacterial activities of isolates highlight them as candidates for further investigation. Therefore both ethylacetate extracts were subjected to HPLC fractionation followed by LC/MS analysis of the active compounds. The range of inhibited wells for selected strains revealed that the tested extracts exhibited the strongest antimicrobial activity against Gram-positive bacterium *Staphylococcus aureus* (inhibited wells until H, strain ST-13) and Gram-negative bacterium *Chromobacterium violaceum* (inhibited wells until G, strain DK-15).

The peak-activity-correlation test (Figure 1) of ST-13 extract revealed that the active fractions after HPLC fractionation were located at retention times 13.0-13.5 min. The dominant peak in HPLC chromatogram appearing at this retention time exhibited UV-VIS maxima at 268 nm and ESI-HRMS



**Figure 1** – Fractionation RP-HPLC chromatogram of tetrangomycin, UV spectrum of tetrangomycin with the max at 268 nm, and ESI-HRMS spectrum, showing the prominent ion clusters for  $[M+H]^+$  at  $m/z$  339.0861.

spectrum showing the prominent ion clusters for  $[M+H]^+$  at  $m/z$  339.0861. These data correlated to **tetrangomycin**.

The second peak-activity-correlation test (Figure 2) of DK-15 extract revealed that the active fractions were located between retention times 16.0–16.5 min. The peak appearing at this retention times exhibit UV-VIS maxima at 364 nm and ESI-HRMS spectrum showing the prominent ion clusters for  $[M+H]^+$  at  $m/z$  743.4268. These data correlated to **factumycin**.

#### Characterization and identification of antibiotic-producing isolates ST13 and DK15

Both strains were observed to be Gram-positive, aerobic, non-motile and with abundant substrate and aerial mycelium typical for the genus *Streptomyces*. In the present study, isolates DK15 and ST13 were subjected to the molecular, protein and polyphasic identification. The 16S rRNA genes were sequenced and compared with the 16S rRNA sequences of previously described the most related type cultures. A comparison of the sequences using Genbank database showed the highest similarity of ST13 with *Streptomyces ederenis* DSM-40741T (99%, 1450 of 1460 bases were identical, 2 gaps) and *Streptomyces phaeochromogenes* DSM-40073T (99%, 1448/1463, 4 gaps). Isolate DK15 showed identical sequences with *Streptomyces globosus* DSM-40815T and *Streptomyces toxytricini* DSM-40178T. A maximum likelihood phylogenetic analysis confirmed these findings (Figure 3). The sequences of 16S rRNA gene were

deposited under accession numbers KX527570 for DK15 and KX527568 for ST13. The MSP dendrogram showed high concordance with the clustering and topology of the 16S rRNA gene tree, and clustered strain ST-13 with *Streptomyces ederenis* (DSM-40741T) and strain DK-15 with *Streptomyces globosus* (DSM-40815T) (Figure 3). These results were in concordance with cultural and physiological features of the tested strains (Table 2) and the most related type strains (data available in Compendium of Actinobacteria).<sup>25</sup>

Activity of the extracellular enzymes was quantified using the Api Zym<sup>®</sup> and Api Coryne<sup>®</sup> stripes. A huge enzymatic potential was discovered within the tested streptomycetes. It was found that isolates showed high alkaline phosphatase, esterase, leucinearylamidase, valinearylamidase, glucosidase, N-acetyl-glucoseamidase and urease activity (> 40 nmol).

From the available literature we found out, that isolate DK15 identified as *Streptomyces globosus* DK15 represent a new source of factumycin antibiotic and isolate ST13 identified as *Streptomyces ederenis* ST13 represent a new source of tetrangomycin antibiotic. The results from present study indicated, that during our research streptomycete programme we found out two new producers of polyketide antibacterial compounds.

#### Discussion

Using crude ethylacetate extracts prepared from ST13 and DK15 cells, the high antimicrobial activities were detected






Figure 2 – Fractionation RP-HPLC chromatogram of factumycin, UV spectrum of factumycin with the max. at 364 nm, and ESI-HRMS spectrum, showing the prominent ion clusters for  $[M+H]^+$  at  $m/z$  743.4268.




Figure 3 – Comparison between 16S rRNA phylogenetic tree and the MSP dendrogram. A. Mean spectra projection (MSP) dendrogram, B. 16S rRNA based phylogenetic tree of *Streptomyces* type strains, T1-T11 – DSM type cultures used for grouping of *Streptomyces* species, T1 - *Streptomyces viridis* DSM-42078 (T), T2 - *S. phaeochromogenes* DSM-40788 (T), T3 - *S. ederenensis* DSM-40741 (T), T4 - *S. iakyrus* DSM-40482 (T), T5 - *S. griseochromogenes* DSM-40499 (T), T6 - *S. gougerotii* DSM-40324 (T), T7 - *S. albus* DSM-40313 (T), T8 - *S. diastaticus* DSM-40495 (T), T9 - *S. alboflavus* DSM-40045 (T), T10 - *S. toxytricini* DSM-40178 (T), T11 - *S. globosus* DSM-41122 (T).

**Table 2 – Cultural, morphological and physiological characteristics of strains DK-15 and ST-13.**

Test	Labeling of strains	
	DK15	ST13
Gram staining	+	+
Spore chain	RF	RF
Aerial mycelium	ISP2-ISP5 beige red, ISP6-ISP7 no	ISP2-ISP5,7 grey, ISP6 none
Substrate mycelium	ISP2,7 yellow, ISP3-6 ivory	ISP2-7 brown
Soluble pigment color	-	ISP6-7 brown
Melanin production	-	+
NaCl tolerance up to:	2.5	5.0
Utilization of carbon sources		
Glucose	+	+
Raffinose	-	+
Arabinose	-	+
Inositol	-	+
Mannose	-	+
Fructose	+	+
Rhamnose	+	+
Sucrose	-	+
Xylose	-	-
Cellulose	-	-
Optimal pH	7	7
Optimal temperature	30 °C	28 °C

+ positive growth, - negative growth, ISP - International Streptomyces Project

against Gram-positive and Gram-negative bacteria. Chromatographic analysis of crude extract of our strains ST13 and DK15 led to the identification of the antibacterial compounds factumycin and tetrangomycin with polyketide structure.

Polyketides constitute an important group of secondary metabolites highly relevant as therapeutics for clinical use as many of them are potent antibiotic, antifungal, antitumor, immunosuppressant, antiviral or antiparasitic agents.<sup>26,27</sup> Many polyketide secondary metabolites are produced by a group of filamentous gram-positive bacteria of the Actinomycetales order.<sup>28</sup> Tetrangomycin, one of the first members of angucyclinones, was previously isolated from the culture broth of *Streptomyces rimosus*, or *S. cyanogenus* S-136.<sup>7,29</sup> Özakin et al.<sup>11</sup> reported high antimicrobial activity of crude extract which contained tetrangomycin from *Streptomyces* sp. CAH29 against MRSA. Our results also indicate highest activity against *S. aureus*. Activity of tetrangomycin is probably based on inhibition of the staphyloxanthin production by *S. aureus* and there is a potential of use this substance in new MRSA drug.

Factumycin were previously found in *S. collinus*, *Streptomyces* sp. WAC5292, and *S. lavendulae*.<sup>30,15,13</sup> High antimicrobial activity of the factumycin was reported mainly against Gram negative bacteria.<sup>15</sup> In our case, inhibition of gram negative as well as gram positive species (*M. smegmatis*, *B. subtilis*) was detected however it depends on testing strains.

The search for polyketide antibiotics requires the screening and reliable identification of *Streptomyces* strains which has always been considered to be very difficult<sup>31</sup>. Despite specificity of 16S rRNA region, there exist some drawbacks and inconsistencies in this method of identification.<sup>32</sup> In our study,

sequences of 16S rRNA gene did not allow us identification of strain DK15. Recently, study of Loucif et al.<sup>24</sup> demonstrated that protein analysis using MALDI-TOF-MS can be used for the rapid identification of *Streptomyces* species. Comparison of protein spectra together with analysis of 16S rRNA gene and detailed morphological, physiological and enzymatic analysis provide very exact results about taxonomic position of streptomycete strains we analyzed. Strain ST13 was identified as *S. ederenis* and strain DK15 as *S. globosus*. Tetrangomycin have not been previously reported from *S. ederenis* (producer of moenomycin, bambermycin, and phaeochromycin)<sup>33-35</sup> and factumycin from *S. globosus* (producer of actinomycin, and 2-deoxystreptomycin aminocyclitol aminoglycoside antibiotic)<sup>36</sup>, and therefore we reported a new producers of these high active antibacterial compounds. These strains were isolated from the forest soils in national parks. Such soils can be considered as rich deposits of novel active strains with high antimicrobial activity.

### Conflict of interest

The authors have not declared any conflict of interest.

### Acknowledgments

The authors are grateful to the Helmholtz Centre for Infection Research (Microbial Strain Collection Group), Braunschweig, Germany for the scholarship and support of the results. This study was also supported by the Scientific Grant Agency of the Ministry of Education of the Slovak Republic and of the Slovak Academy of Sciences grant no. VEGA 1/0305/17. The authors are grateful to Ms. Martina Drexlerova for the editing and English corrections.

### Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.bjm.2017.12.007](https://doi.org/10.1016/j.bjm.2017.12.007).

### REFERENCES

- Demain AL, Sanchez S. Microbial drug discovery: 80 years of progress. *J Antibiot.* 2009;62(1):5–16, <http://dx.doi.org/10.1038/ja.2008.16>.
- Olano C, Méndez C, Salas JA. Molecular insights on the biosynthesis of antitumor compounds by actinomycetes. *Microb Biotechnol.* 2011;4(2):144–164, <http://dx.doi.org/10.1111/j.1751-7915.2010.00231.x>.
- Bérty J. Bioactive microbial metabolites. *J Antibiot.* 2005;58(1):1–26, <http://dx.doi.org/10.1038/ja.2005.1>.
- Chen M, Wang G, Dai S, Xie L, Li X. Polyketide antibiotics produced by polyketide synthase in streptomyces –a review. *Wei Sheng Wu Xue Bao.* 2009;49(12):1555–1563, <https://www.ncbi.nlm.nih.gov/pubmed/20222438>.
- Rohr J, Thiericke R. Angucycline group antibiotics. *Nat Prod Rep.* 1992;9(2):103–137, <http://dx.doi.org/10.1039/np9920900103>.
- Dann M, Lefemine DV, Barbatschi FM, et al. Tetrangomycin, a new quinone antibiotic. *Antimicrob Agents Chemother.*

- 1964;5:832–835, <https://www.ncbi.nlm.nih.gov/labs/articles/5883506/>.
7. Kuntsmann MP, Mitscher LA. The structural characterization of tetrangomycin and tetrangulol. *J Org Chem*. 1966;31(9):2920–2925, <http://dx.doi.org/10.1021/jo01347a043>.
  8. Manivasagan P, Venkatesan J, Sivakumar K, Kim SK. Pharmaceutically active secondary metabolites of marine actinobacteria. *Microbiol Res*. 2014;169(4):262–278, <http://dx.doi.org/10.1016/j.micres.2013.07.014>.
  9. Fotso S, Fotso-Fondja Yao CB, Helmke E, Laatsch H. 2-Hydroxy-luisol A, a new quinone-derived tetraol from a marine Streptomyces sp. and oxidation products of luisol A. *Z Naturforsch*. 2011;66(6):629–634, <http://dx.doi.org/10.5560/znb.2011.66b0629>.
  10. Krohn K, Rohr J. Angucyclines: Total syntheses, new structures, and biosynthetic studies of an emerging new class of antibiotics. *Top Curr Chem*. 1997;188:127–195, <http://dx.doi.org/10.1002/chin.199737344>.
  11. Özakın S, Davis RW, Umile TP, et al. The isolation of tetrangomycin from terrestrial Streptomyces sp CAH29: evaluation of antioxidant, anticancer, and anti-MRSA activity. *Med Chem Res*. 2016;25(12):2872–2881, <http://dx.doi.org/10.1007/s00044-016-1708-6>.
  12. Kimura K, Iwatsuki M, Nagai T, et al. A small molecule inhibitor of the bacterial type III secretion system protects against in vivo infection with Citrobacter rodentium. *J Antibiot*. 2010;64(2):197–203, <http://dx.doi.org/10.1038/ja.2010.155>.
  13. Gullo VP, Zimmerman SB, Dewey RS, Hensens O, Cassidy PJ. Factumycin, a new antibiotic (A40A): fermentation, isolation and antibacterial spectrum. *J Antibiot*. 1982;35(12):1705–1707, <http://dx.doi.org/10.7164/antibiotics.35.1705>.
  14. Kakeya H, Morishita M, Ikeno A, Kobinata K, Yano T, Osada H. Factumycin and its new derivate RK-1009 enhance threonine-phosphorylation of a 60-kDa protein in Streptomyces griseus. *J Antibiot*. 1998;51(10):963–966, <http://dx.doi.org/10.7164/antibiotics.51.963>.
  15. Thaker MN, Garcia M, Koteva KP, Wright GD. Biosynthetic gene cluster and antimicrobial activity of the elfamycin antibiotic factumycin. *Med Chem Comm*. 2012;3(8):1020–1026, <http://dx.doi.org/10.1039/c2md20038d>.
  16. Poosarla A, Venkata-Ramana L, Murali-Krishna M. Isolation of potent antibiotic producing actinomycetes from marine sediments of Andaman and Nicobar marine islands. *J Microbiol Antimicrob*. 2013;5(1):6–12, <http://dx.doi.org/10.5897/jma11.075>.
  17. Shirling ET, Gottlieb D. Methods for characterization of Streptomyces species. *Int J System Evol Microbiol*. 1966;16(3):313–340, <http://dx.doi.org/10.1099/00207713-16-3-313>.
  18. Cazin J, Wiemer DF, Howard JJ. Isolation, growth characteristics, and long-term storage of fungi cultivated by attine ants. *App Env Micro*. 1989;55(6):1346–1350, <http://aem.asm.org/content/55/6/1346>.
  19. Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. *Nat Protoc*. 2008;3(2):163–175, <http://dx.doi.org/10.1038/nprot.2007.521>.
  20. Sambrook J, Fritsch EF, Maniatis T. *Molecular cloning: A laboratory manual*. NY: Cold Spring Harbor Laboratory Press; 1989.
  21. Cook AE, Meyers PR. Rapid identification of filamentous actinomycetes to the genus level using genus-specific 16S rRNA gene restriction fragment patterns. *Int J Syst Evol Microbiol*. 2003;53(6):1907–1915, doi: org/10.1099/ijs.0.02680-0.
  22. Felsenstein J. Evolutionary trees from DNA sequences: A maximum likelihood approach. *J Mol Evol*. 1981;17(6):368–376, <http://dx.doi.org/10.1007/bf01734359>.
  23. Guindon S, Gascuel O. A simple fast and accurate algorithm to estimate large phylogenies by maximum likelihood. *Syst Biol*. 2003;52(5):696–704, <http://dx.doi.org/10.1080/10635150390235520>.
  24. Loucif L, Bendjama E, Gacemi-Kirane D, Rolain JM. Rapid identification of Streptomyces isolates by MALDI-TOF MS. *Microbiol Res*. 2014;169(12):940–947, <http://dx.doi.org/10.1016/j.micres.2014.04.004>.
  25. Wink J. DSMZ - Compendium of Actinobacteria. <http://www.dsmz.de/bacterial-diversity/compendium-ofactinobacteria.html>. Published 2014. Accessed 25 May 2017.
  26. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. *J Nat Prod*. 2007;70(3):461–477, <http://dx.doi.org/10.1021/np068054v>.
  27. Olano C, Méndez C, Salas JA. Antitumor compounds from actinomycetes: from gene clusters to new derivatives by combinatorial biosynthesis. *Nat Prod Rep*. 2009;26(5):628–660, <http://dx.doi.org/10.1039/b822528a>.
  28. Gomes ES, Schuch V, de Macedo Lemos EG. Biotechnology of polyketides: new breath of life for the novel antibiotic genetic pathways discovery through metagenomics. *Braz J Microbiol*. 2013;44(4):1007–1034, <http://dx.doi.org/10.1590/s1517-83822013000400002>.
  29. Shaaban KA, Stamatkin C, Damodaran C, Rohr J. 11-Deoxylandomycinone and landomycins XZ, new cytotoxic angucyclin (on) es from a Streptomyces cyanogenus K62 mutant strain. *J Antibiot*. 2011;64(1):141–150, <http://dx.doi.org/10.1038/ja.2010.121>.
  30. Iffime D, Kulik A, Härtner T, et al. Identification and activation of novel biosynthetic gene clusters by genome mining in the kirromycin producer Streptomyces collinus Tü 365. *J Ind Microbiol Biotechnol*. 2016;43(2–3):277–291, <http://dx.doi.org/10.1007/s10295-015-1685-7>.
  31. Kim KO, Shin KS, Kim MN, et al. Reassessment of the status of Streptomyces setonii and reclassification of Streptomyces fimicarius as a later synonym of Streptomyces setonii and Streptomyces albovinaceus as a later synonym of Streptomyces globisporus based on combined 16S rRNA/gyrB gene sequence analysis. *Int J Syst Evol Microbiol*. 2012;62(12):2978–2985, <http://dx.doi.org/10.1099/ijs.0.040287-0>.
  32. Stackebrandt E. Taxonomic parameters revisited: tarnished gold standards. *Microbiol Today*. 2006;8: 6–9. <https://www.tib.eu/en/search/id/BLSE%3ARN196956371/Taxonomic-parameters-revisited-tarnished-gold-standards/>.
  33. Dietrich J, Mracek M, Sukatsch D, Nesemann G. Process for the preparation of moenomycin. 1976. U.S. Patent No. 3, 992, 263. Washington, DC: U.S. Patent and Trademark Office.
  34. Huber G, Schecht U, Weidenmuller HL, Schmidt-Thom J, Duphorn J, Tschesche R. Moenomycin, a new antibiotic II. Characterization and chemistry. *Antimicrob Agent Chemother*. 1965;5:737–742, <https://www.ncbi.nlm.nih.gov/pubmed/5883491>.
  35. Ritacco FV, Eveleigh DE. Molecular and phenotypic comparison of phaeochromycin-producing strains of Streptomyces phaeochromogenes and Streptomyces ederensis. *J Ind Microbiol Biotechnol*. 2008;35(9):931–945, <http://dx.doi.org/10.1007/s10295-008-0367-0>.
  36. El-Khatib WF, Abulwafa M, Yassien MAM, Hassouna NA. A promising 2-deoxystreptomycin aminocyclitol aminoglycoside antibiotic from Streptomyces globosus isolate with antibacterial antifungal activities. *Egypt J Biotechnol*. 2008;29:48–74.